PDCD1 and arthritic joint disease: We postulated that PD-L1-MSA treatment could effectively attenuate T cell activation by blocking the interference of sPD-1 with the PD-1/PD-L1 axis, thereby alleviating the inflammatory response and mitigating arthritis development in mice.